A detailed history of 9258 Wealth Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, 9258 Wealth Management, LLC holds 3,118 shares of VRTX stock, worth $1.48 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
3,118
Previous 2,874 8.49%
Holding current value
$1.48 Million
Previous $1.2 Million 21.65%
% of portfolio
0.23%
Previous 0.19%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 02, 2024

BUY
$392.81 - $485.53 $95,845 - $118,469
244 Added 8.49%
3,118 $1.46 Million
Q1 2024

May 03, 2024

BUY
$407.69 - $446.08 $40,769 - $44,608
100 Added 3.6%
2,874 $1.2 Million
Q4 2023

Feb 06, 2024

SELL
$343.0 - $410.68 $686 - $821
-2 Reduced 0.07%
2,774 $1.13 Million
Q3 2023

Nov 08, 2023

SELL
$338.18 - $362.46 $6,087 - $6,524
-18 Reduced 0.64%
2,776 $965,000
Q1 2023

May 03, 2023

SELL
$283.23 - $323.1 $1,982 - $2,261
-7 Reduced 0.25%
2,794 $880,000
Q4 2022

Feb 03, 2023

SELL
$285.76 - $321.48 $22,003 - $24,753
-77 Reduced 2.68%
2,801 $808,000
Q3 2022

Nov 08, 2022

SELL
$273.83 - $305.53 $56,408 - $62,939
-206 Reduced 6.68%
2,878 $833,000
Q2 2022

Aug 04, 2022

SELL
$234.96 - $292.55 $52,866 - $65,823
-225 Reduced 6.8%
3,084 $869,000
Q1 2022

May 13, 2022

SELL
$221.42 - $260.97 $45,833 - $54,020
-207 Reduced 5.89%
3,309 $864,000
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $38,765 - $48,935
219 Added 6.64%
3,516 $772,000
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $276,256 - $309,153
1,523 Added 85.85%
3,297 $598,000
Q2 2021

Aug 13, 2021

BUY
$187.49 - $221.1 $38,060 - $44,883
203 Added 12.92%
1,774 $358,000
Q1 2021

May 11, 2021

BUY
$207.02 - $241.31 $32,709 - $38,126
158 Added 11.18%
1,571 $338,000
Q4 2020

Feb 10, 2021

BUY
$207.01 - $276.09 $292,505 - $390,115
1,413 New
1,413 $334,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track 9258 Wealth Management, LLC Portfolio

Follow 9258 Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 9258 Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on 9258 Wealth Management, LLC with notifications on news.